Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)
Prospective trial shows sensitive detection of minimum residual disease using EasyM in multiple myeloma patients, indicating clinical applicability.
Key Points
Evaluate the clinical applicability of peripheral residual disease assessments using clonotypic mass spectrometry (EasyM) in newly diagnosed multiple myeloma patients.
Prospective, multi-center, investigator-initiated study
Enrolled transplant eligible and ineligible patients within 4 months of treatment initiation
PRD assessed using EasyM at multiple time-points including post-autologous stem cell transplant
54 out of 55 pre-screened patients had a unique clonotypic peptide identified
83% of patients achieved ≥VGPR by visit 2, detecting M protein in patients with negative SIFE
Concordance observed between BM MRD assessments and PRD results using EasyM in 6 out of 9 matched cases